Combination treatment for acute myeloid leukemia (AML)
US9956243B2 · kind B2 · utility
1Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2014 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Apr 2, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example:and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.